Michael Altorfer, CEO of the Swiss Biotech Association, a membership organisation representing the interests of the Swiss biotech industry, discusses the evolution of the biotech sector in Switzerland, how the country’s ecosystem has helped foster success stories like Actelion, and the multilateral work being done to improve intellectual property protection in China and the rest of the world.
Switzerland is one of the few biotech hubs that is very diverse and complete in its positioning. Looking at indication-specific research or different modalities, you will find activities, companies and research groups in all of them
